Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in anxiety disorders.

David M Christmas1, Sean D Hood

  • 1School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia.

Recent Patents on CNS Drug Discovery
|January 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using the theory of positive disintegration's 'dynamisms' to gauge retrospective suicide lived experience.

Frontiers in psychology·2026
Same author

Real-World Applications of Pharmacogenomics in Paediatrics.

Journal of paediatrics and child health·2025
Same author

PharmacoGENEtics in Youth Depression (GENE-YD) Study protocol: a pilot triple-blinded randomised controlled trial using pharmacogenetics to tailor antidepressant treatment in young Australians.

BMJ open·2025
Same author

Exploring the perspectives of young adults on mental healthcare and systemic health, education, and social challenges in Australia: a qualitative study.

BMC health services research·2025
Same author

Corrigendum: Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices.

Frontiers in pharmacology·2025
Same author

Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices.

Frontiers in pharmacology·2025
Same journal

Editorial (Thematic Issue: From Old Cannabinoids to Emerging New Synthetic Derivatives with Potential Therapeutic Application in Neurological Disorders).

Recent patents on CNS drug discovery·2016
Same journal

Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.

Recent patents on CNS drug discovery·2016
Same journal

Endocannabinoid System in Neurological Disorders.

Recent patents on CNS drug discovery·2016
Same journal

Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.

Recent patents on CNS drug discovery·2016
Same journal

Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response.

Recent patents on CNS drug discovery·2016
Same journal

Neuropharmacological Properties of Withania somnifera - Indian Ginseng: An Overview on Experimental Evidence with Emphasis on Clinical Trials and Patents.

Recent patents on CNS drug discovery·2016
See all related articles

New anxiolytic drugs targeting novel neurotransmitter systems show promise for treating anxiety disorders, offering improved efficacy and fewer side effects than current options.

Area of Science:

  • Neuropharmacology
  • Anxiety Disorders
  • Drug Development

Background:

  • Anxiety disorders are prevalent and significantly impact quality of life.
  • Existing anxiolytic medications have limitations regarding efficacy and side effect profiles.
  • Emerging research into neurotransmitter systems offers new therapeutic avenues.

Purpose of the Study:

  • To review recent patents and peer-reviewed literature on anxiolytic drug development.
  • To outline current areas of interest and future directions in anxiolytic pharmacology.
  • To provide an overview of neuropharmacological advancements for anxiety disorders.

Main Methods:

  • Searched patent databases for 17 neurotransmitters and 23 compounds (May 2003-May 2005).
  • Conducted literature searches on PubMed and Google Scholar using similar parameters.

Related Experiment Videos

  • Grouped findings by neurotransmitter systems for comprehensive analysis.

    • Main Results:

    • Identified key neurotransmitter systems and compounds of recent interest in anxiolytic research.
    • Highlighted novel targets and mechanisms emerging from patent and scientific literature.
    • Detailed recent developments in the neuropharmacology of anxiety disorders.

    Conclusions:

    • Advances in understanding neurotransmitter systems are expanding the potential for effective anxiolytic treatments.
    • Future anxiolytic drug development is likely to focus on novel targets and improved therapeutic profiles.
    • This review provides a snapshot of recent innovations in the field of anxiety disorder pharmacotherapy.